| ■ 영문 제목 : Global HDAC Inhibitors Market 2023-2027
|
 | ■ 상품코드 : IRTNTR72719-23
■ 조사/발행회사 : Technavio
■ 발행일 : 2023년 1월
■ 페이지수 : 약120
■ 작성언어 : 영문
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (24시간 이내)
■ 조사대상 지역 : 북미, 유럽, 아시아 태평양, 기타 지역
■ 산업 분야 : 의료
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1명 열람용) | USD2,500 ⇒환산￦3,375,000 | 견적의뢰/주문/질문 |
| Enterprise License (동일기업내 공유가능) | USD4,000 ⇒환산￦5,400,000 | 견적의뢰/주문/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
Technavio사는 세계의 HDAC 저해제 시장 규모가 2022년에서 2027년 사이에 172.61백만 달러에 달하며, 예측 기간 동안 연평균 7.73% 성장할 것으로 예상하고 있습니다. 본 조사 보고서는 세계의 HDAC 저해제 시장에 대해 조사 및 분석을 실시하여, 개요, 시장 현황, 시장 규모 예측, 과거 시장 규모, Five Force 분석, 투여 경로별 (경구, 비경구) 분석, 유통 채널별 (병원 약국, 소매 약국, 온라인 약국, 기타) 분석, 고객 현황, 지역별 현황 (북미, 유럽, 아시아 태평양, 기타 지역, 미국, 캐나다, 영국, 독일, 중국) 분석, 성장 요인/과제/동향, 기업 현황, 기업 분석 등의 내용을 게재하고 있습니다. 또한 본 조사 보고서는 Actrotech Biopharma Inc., AstraZeneca Plc, Bio Techne Corp., BioVision Inc., Bristol Myers Squibb Co., Celleron Therapeutics Ltd., Curis Inc., Huya Bioscience International LLC, InvivoGen Corp., Italfarmaco Spa, Medivir AB, Merck and Co. Inc., Novartis AG, Onxeo SA, Shenzhen Chipscreen Biotechnology Co. Ltd., Syndax Pharmaceuticals Inc., Tokyo Chemical Industry Co. Ltd., Viracta Therapeutics Inc., Xynomic Pharmaceuticals (Nanjing) Co. Ltd. ., Cetya Therapeutics Inc.와 같은 기업 정보를 포함하고 있습니다.
・개요
・시장 현황
・시장 규모 예측
・과거 시장 규모
・Five Force 분석
・세계의 HDAC 저해제 시장 규모 : 투여 경로별
- 경구 투여 HDAC 저해제의 시장 규모
- 비경구 투여 HDAC 저해제의 시장 규모
・세계의 HDAC 저해제 시장 규모 : 유통 채널별
- 병원 약국 채널의 시장 규모
- 소매 약국 채널의 시장 규모
- 온라인 약국 채널의 시장 규모
- 기타 채널의 시장 규모
・지역별 현황
- 북미의 HDAC 저해제 시장 규모
- 유럽의 HDAC 저해제 시장 규모
- 아시아 태평양의 HDAC 저해제 시장 규모
- 기타 지역의 HDAC 저해제 시장 규모
- 미국의 HDAC 저해제 시장 규모
- 캐나다의 HDAC 저해제 시장 규모
- 영국의 HDAC 저해제 시장 규모
- 독일의 HDAC 저해제 시장 규모
- 중국의 HDAC 저해제 시장 규모
・성장 요인/과제/동향
・기업 현황
・기업 분석
Technavio 사는 이익, 가격, 경쟁, 프로모션과 같은 주요 매개 변수를 분석하여, 다수의 소스로부터 데이터를 조사, 통합 및 합산하여 HDAC 저해제 시장에 대한 상세하고 종합적인 결과를 제공합니다. 또한, 주요 산업의 영향 요인을 분석하여 시장의 다양한 관점을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있으며, 1차 및 2차에 걸친 광범위한 조사 결과입니다. 덧붙여 Technavio 사의 시장 조사 보고서는 정확한 HDAC 저해제 시장 성장을 예측하기 위해, 정성적 및 정량적 조사를 사용하여, 명확한 경쟁 현황과 상세한 벤더 선택 방법 및 분석을 제공합니다. |
■ 보고서 개요Global HDAC (Histone Deacetylase) Inhibitors Market 2023-2027Technavio has been monitoring the HDAC (histone deacetylase) inhibitors market and is forecast to grow by $172.61 mn during 2022-2027, accelerating at a CAGR of 7.73% during the forecast period. Our report on the HDAC (histone deacetylase) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high target affinity and specificity, high prevalence of oncology indications, and development of novel drug delivery systems and combination therapies.
Technavio’s HDAC (histone deacetylase) inhibitors market is segmented as below:
By Route Of Administration
• Oral HDAC inhibitors
• Parenteral HDAC inhibitors
By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
• Others
By Geography
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies the growing geriatric population as one of the prime reasons driving the HDAC (histone deacetylase) inhibitors market growth during the next few years. Also, research grants and funding and growing awareness about cancer will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the HDAC (histone deacetylase) inhibitors market covers the following areas:
• HDAC (histone deacetylase) inhibitors market sizing
• HDAC (histone deacetylase) inhibitors market forecast
• HDAC (histone deacetylase) inhibitors market industry analysis
Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading HDAC (histone deacetylase) inhibitors market vendors that include Acrotech Biopharma Inc., AstraZeneca Plc, Bio Techne Corp., BioVision Inc., Bristol Myers Squibb Co., Celleron Therapeutics Ltd., Curis Inc., Huya Bioscience International LLC, InvivoGen Corp., Italfarmaco Spa, Medivir AB, Merck and Co. Inc., Novartis AG, Onxeo SA, Shenzhen Chipscreen Biotechnology Co. Ltd., Syndax Pharmaceuticals Inc., Tokyo Chemical Industry Co. Ltd., Viracta Therapeutics Inc., Xynomic Pharmaceuticals (Nanjing) Co. Ltd., and Cetya Therapeutics Inc. Also, the HDAC (histone deacetylase) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
■ 보고서 목차• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global HDAC (histone deacetylase) inhibitors market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global HDAC (histone deacetylase) inhibitors market 2017 – 2021 ($ million)
o 4.2 Route of administration Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Route of administration Segment 2017 – 2021 ($ million)
o 4.3 Distribution Channel Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Route of Administration
o 6.1 Market segments
o Exhibit 30: Chart on Route of Administration – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Route of Administration – Market share 2022-2027 (%)
o 6.2 Comparison by Route of Administration
o Exhibit 32: Chart on Comparison by Route of Administration
o Exhibit 33: Data Table on Comparison by Route of Administration
o 6.3 Oral HDAC inhibitors – Market size and forecast 2022-2027
o Exhibit 34: Chart on Oral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Oral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Oral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Oral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
o 6.4 Parenteral HDAC inhibitors – Market size and forecast 2022-2027
o Exhibit 38: Chart on Parenteral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Parenteral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Parenteral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Parenteral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Route of Administration
o Exhibit 42: Market opportunity by Route of Administration ($ million)
• 7 Market Segmentation by Distribution Channel
o 7.1 Market segments
o Exhibit 43: Chart on Distribution Channel – Market share 2022-2027 (%)
o Exhibit 44: Data Table on Distribution Channel – Market share 2022-2027 (%)
o 7.2 Comparison by Distribution Channel
o Exhibit 45: Chart on Comparison by Distribution Channel
o Exhibit 46: Data Table on Comparison by Distribution Channel
o 7.3 Hospital pharmacies – Market size and forecast 2022-2027
o Exhibit 47: Chart on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 48: Data Table on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Chart on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
o Exhibit 50: Data Table on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
o 7.4 Retail pharmacies – Market size and forecast 2022-2027
o Exhibit 51: Chart on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 52: Data Table on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Chart on Retail pharmacies – Year-over-year growth 2022-2027 (%)
o Exhibit 54: Data Table on Retail pharmacies – Year-over-year growth 2022-2027 (%)
o 7.5 Online pharmacies – Market size and forecast 2022-2027
o Exhibit 55: Chart on Online pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 56: Data Table on Online pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Chart on Online pharmacies – Year-over-year growth 2022-2027 (%)
o Exhibit 58: Data Table on Online pharmacies – Year-over-year growth 2022-2027 (%)
o 7.6 Others – Market size and forecast 2022-2027
o Exhibit 59: Chart on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 60: Data Table on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Chart on Others – Year-over-year growth 2022-2027 (%)
o Exhibit 62: Data Table on Others – Year-over-year growth 2022-2027 (%)
o 7.7 Market opportunity by Distribution Channel
o Exhibit 63: Market opportunity by Distribution Channel ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 65: Chart on Market share by geography 2022-2027 (%)
o Exhibit 66: Data Table on Market share by geography 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 67: Chart on Geographic comparison
o Exhibit 68: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 69: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 70: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 71: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 72: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 73: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 74: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 75: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 76: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 77: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 78: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 79: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 80: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 81: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 82: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 83: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 84: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 85: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 86: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 87: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 88: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Canada – Market size and forecast 2022-2027
o Exhibit 89: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 90: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 91: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 92: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.9 UK – Market size and forecast 2022-2027
o Exhibit 93: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 95: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 96: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.10 Germany – Market size and forecast 2022-2027
o Exhibit 97: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 98: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 99: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 100: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.11 China – Market size and forecast 2022-2027
o Exhibit 101: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 102: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 103: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 104: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity by geography
o Exhibit 105: Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 106: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 107: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 108: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 109: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 110: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 111: Matrix on vendor position and classification
o 12.3 Acrotech Biopharma Inc.
o Exhibit 112: Acrotech Biopharma Inc. – Overview
o Exhibit 113: Acrotech Biopharma Inc. – Product / Service
o Exhibit 114: Acrotech Biopharma Inc. – Key offerings
o 12.4 AstraZeneca Plc
o Exhibit 115: AstraZeneca Plc – Overview
o Exhibit 116: AstraZeneca Plc – Product / Service
o Exhibit 117: AstraZeneca Plc – Key news
o Exhibit 118: AstraZeneca Plc – Key offerings
o 12.5 Bristol Myers Squibb Co.
o Exhibit 119: Bristol Myers Squibb Co. – Overview
o Exhibit 120: Bristol Myers Squibb Co. – Product / Service
o Exhibit 121: Bristol Myers Squibb Co. – Key news
o Exhibit 122: Bristol Myers Squibb Co. – Key offerings
o 12.6 Celleron Therapeutics Ltd.
o Exhibit 123: Celleron Therapeutics Ltd. – Overview
o Exhibit 124: Celleron Therapeutics Ltd. – Key offerings
o 12.7 Curis Inc.
o Exhibit 125: Curis Inc. – Overview
o Exhibit 126: Curis Inc. – Product / Service
o Exhibit 127: Curis Inc. – Key offerings
o 12.8 Huya Bioscience International LLC
o Exhibit 128: Huya Bioscience International LLC – Overview
o Exhibit 129: Huya Bioscience International LLC – Product / Service
o Exhibit 130: Huya Bioscience International LLC – Key offerings
o 12.9 Italfarmaco Spa
o Exhibit 131: Italfarmaco Spa – Overview
o Exhibit 132: Italfarmaco Spa – Product / Service
o Exhibit 133: Italfarmaco Spa – Key offerings
o 12.10 Medivir AB
o Exhibit 134: Medivir AB – Overview
o Exhibit 135: Medivir AB – Product / Service
o Exhibit 136: Medivir AB – Key offerings
o 12.11 Merck and Co. Inc.
o Exhibit 137: Merck and Co. Inc. – Overview
o Exhibit 138: Merck and Co. Inc. – Business segments
o Exhibit 139: Merck and Co. Inc. – Key news
o Exhibit 140: Merck and Co. Inc. – Key offerings
o Exhibit 141: Merck and Co. Inc. – Segment focus
o 12.12 Novartis AG
o Exhibit 142: Novartis AG – Overview
o Exhibit 143: Novartis AG – Business segments
o Exhibit 144: Novartis AG – Key offerings
o Exhibit 145: Novartis AG – Segment focus
o 12.13 Onxeo SA
o Exhibit 146: Onxeo SA – Overview
o Exhibit 147: Onxeo SA – Product / Service
o Exhibit 148: Onxeo SA – Key offerings
o 12.14 Shenzhen Chipscreen Biotechnology Co. Ltd.
o Exhibit 149: Shenzhen Chipscreen Biotechnology Co. Ltd. – Overview
o Exhibit 150: Shenzhen Chipscreen Biotechnology Co. Ltd. – Product / Service
o Exhibit 151: Shenzhen Chipscreen Biotechnology Co. Ltd. – Key offerings
o 12.15 Syndax Pharmaceuticals Inc.
o Exhibit 152: Syndax Pharmaceuticals Inc. – Overview
o Exhibit 153: Syndax Pharmaceuticals Inc. – Key offerings
o 12.16 Viracta Therapeutics Inc.
o Exhibit 154: Viracta Therapeutics Inc. – Overview
o Exhibit 155: Viracta Therapeutics Inc. – Product / Service
o Exhibit 156: Viracta Therapeutics Inc. – Key offerings
o 12.17 Xynomic Pharmaceuticals (Nanjing) Co. Ltd.
o Exhibit 157: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. – Overview
o Exhibit 158: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. – Product / Service
o Exhibit 159: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 160: Inclusions checklist
o Exhibit 161: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 162: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 163: Research methodology
o Exhibit 164: Validation techniques employed for market sizing
o Exhibit 165: Information sources
o 13.5 List of abbreviations
o Exhibit 166: List of abbreviations
Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by Route of Administration
Exhibits6: Executive Summary – Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global HDAC (histone deacetylase) inhibitors market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Route of administration Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Distribution Channel Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Route of Administration – Market share 2022-2027 (%)
Exhibits31: Data Table on Route of Administration – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Route of Administration
Exhibits33: Data Table on Comparison by Route of Administration
Exhibits34: Chart on Oral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Oral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Oral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Oral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Parenteral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Parenteral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Parenteral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Parenteral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Route of Administration ($ million)
Exhibits43: Chart on Distribution Channel – Market share 2022-2027 (%)
Exhibits44: Data Table on Distribution Channel – Market share 2022-2027 (%)
Exhibits45: Chart on Comparison by Distribution Channel
Exhibits46: Data Table on Comparison by Distribution Channel
Exhibits47: Chart on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits48: Data Table on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits49: Chart on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits50: Data Table on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits51: Chart on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits52: Data Table on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits53: Chart on Retail pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits54: Data Table on Retail pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits55: Chart on Online pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits56: Data Table on Online pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits57: Chart on Online pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits58: Data Table on Online pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits59: Chart on Others – Market size and forecast 2022-2027 ($ million)
Exhibits60: Data Table on Others – Market size and forecast 2022-2027 ($ million)
Exhibits61: Chart on Others – Year-over-year growth 2022-2027 (%)
Exhibits62: Data Table on Others – Year-over-year growth 2022-2027 (%)
Exhibits63: Market opportunity by Distribution Channel ($ million)
Exhibits64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits65: Chart on Market share by geography 2022-2027 (%)
Exhibits66: Data Table on Market share by geography 2022-2027 (%)
Exhibits67: Chart on Geographic comparison
Exhibits68: Data Table on Geographic comparison
Exhibits69: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits70: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits71: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits72: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits73: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits74: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits75: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits76: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits77: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits78: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits79: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits80: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits81: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits82: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits83: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits84: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits85: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits86: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits87: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits88: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits89: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits90: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits91: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits92: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits93: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits95: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits96: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits97: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits98: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits99: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits100: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits101: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits102: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits103: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits104: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits105: Market opportunity by geography ($ million)
Exhibits106: Impact of drivers and challenges in 2022 and 2027
Exhibits107: Overview on Criticality of inputs and Factors of differentiation
Exhibits108: Overview on factors of disruption
Exhibits109: Impact of key risks on business
Exhibits110: Vendors covered
Exhibits111: Matrix on vendor position and classification
Exhibits112: Acrotech Biopharma Inc. – Overview
Exhibits113: Acrotech Biopharma Inc. – Product / Service
Exhibits114: Acrotech Biopharma Inc. – Key offerings
Exhibits115: AstraZeneca Plc – Overview
Exhibits116: AstraZeneca Plc – Product / Service
Exhibits117: AstraZeneca Plc – Key news
Exhibits118: AstraZeneca Plc – Key offerings
Exhibits119: Bristol Myers Squibb Co. – Overview
Exhibits120: Bristol Myers Squibb Co. – Product / Service
Exhibits121: Bristol Myers Squibb Co. – Key news
Exhibits122: Bristol Myers Squibb Co. – Key offerings
Exhibits123: Celleron Therapeutics Ltd. – Overview
Exhibits124: Celleron Therapeutics Ltd. – Key offerings
Exhibits125: Curis Inc. – Overview
Exhibits126: Curis Inc. – Product / Service
Exhibits127: Curis Inc. – Key offerings
Exhibits128: Huya Bioscience International LLC – Overview
Exhibits129: Huya Bioscience International LLC – Product / Service
Exhibits130: Huya Bioscience International LLC – Key offerings
Exhibits131: Italfarmaco Spa – Overview
Exhibits132: Italfarmaco Spa – Product / Service
Exhibits133: Italfarmaco Spa – Key offerings
Exhibits134: Medivir AB – Overview
Exhibits135: Medivir AB – Product / Service
Exhibits136: Medivir AB – Key offerings
Exhibits137: Merck and Co. Inc. – Overview
Exhibits138: Merck and Co. Inc. – Business segments
Exhibits139: Merck and Co. Inc. – Key news
Exhibits140: Merck and Co. Inc. – Key offerings
Exhibits141: Merck and Co. Inc. – Segment focus
Exhibits142: Novartis AG – Overview
Exhibits143: Novartis AG – Business segments
Exhibits144: Novartis AG – Key offerings
Exhibits145: Novartis AG – Segment focus
Exhibits146: Onxeo SA – Overview
Exhibits147: Onxeo SA – Product / Service
Exhibits148: Onxeo SA – Key offerings
Exhibits149: Shenzhen Chipscreen Biotechnology Co. Ltd. – Overview
Exhibits150: Shenzhen Chipscreen Biotechnology Co. Ltd. – Product / Service
Exhibits151: Shenzhen Chipscreen Biotechnology Co. Ltd. – Key offerings
Exhibits152: Syndax Pharmaceuticals Inc. – Overview
Exhibits153: Syndax Pharmaceuticals Inc. – Key offerings
Exhibits154: Viracta Therapeutics Inc. – Overview
Exhibits155: Viracta Therapeutics Inc. – Product / Service
Exhibits156: Viracta Therapeutics Inc. – Key offerings
Exhibits157: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. – Overview
Exhibits158: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. – Product / Service
Exhibits159: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. – Key offerings
Exhibits160: Inclusions checklist
Exhibits161: Exclusions checklist
Exhibits162: Currency conversion rates for US$
Exhibits163: Research methodology
Exhibits164: Validation techniques employed for market sizing
Exhibits165: Information sources
Exhibits166: List of abbreviations
|
| ※본 조사보고서 [세계의 HDAC 저해제 시장 (2023년~2027년)] (코드 : IRTNTR72719-23) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 HDAC 저해제 시장 (2023년~2027년)] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!
